Please login to the form below

Not currently logged in

New Boehringer Ingelheim facility in US

Germany-based pharmaceutical company Boehringer Ingelheim has started the construction of a new safety assessment building in the US

Boehringer Ingelheim, the German pharmaceutical company, has started building a $42.5m safety assessment facility at its campus in Danbury-Ridgefield, Connecticut, in the US.

Dr James Baxter, Boehringer Ingelheim's senior vice president for development in the US, said the 63,000sq ft building would provide a safety testing facility for the new biologic drugs that the company is developing in Connecticut and at its facilities in Laval, Canada; Vienna, Austria and Biberach, Germany. It hopes to open the new building in 2013.

The company is also proposing to build a $65m pilot plant replacement facility nearby, to synthesise and produce the active ingredients it needs for future new drugs. It has not yet secured permission to build the second facility.

However, the company has been offered seven-year tax abatement to stay in the area and when the building is finished, Boehringer Ingelheim will only pay 15 per cent of the taxes assessed on the building for seven years. After this period, it will pay full tax.

24th August 2011


Featured jobs

Subscribe to our email news alerts


Add my company
GCI Health

GCI Health London is a young, vibrant powerhouse in the European industry with a mission to redefine healthcare communications, starting...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch